Pharmacological Basis of OFF Episodes in Parkinson’s Disease – Neurology Live

Related Articles:

• Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States April 5, 2021 J Med Econ. 2021 Apr 5:1. doi: 10.1080/13696998.2021.1913009. Online ahead of print.ABSTRACTAIMS: Within 5 years of initiating carbidopa/levodopa, ∼50% of patients with Parkinson's disease (PD) experience "OFF" episodes; little is known about the cost burden. We investigated the association of "OFF" episodes with patient characteristics, healthcare resource utilization (HCRU), and healthcare costs.METHODS: Analyses used neurologist-provided data from the US-specific 2017…
• Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States April 5, 2021 J Med Econ. 2021 Apr 5:1. doi: 10.1080/13696998.2021.1913009. Online ahead of print.ABSTRACTAIMS: Within 5 years of initiating carbidopa/levodopa, ∼50% of patients with Parkinson's disease (PD) experience "OFF" episodes; little is known about the cost burden. We investigated the association of "OFF" episodes with patient characteristics, healthcare resource utilization (HCRU), and healthcare costs.METHODS: Analyses used neurologist-provided data from the US-specific 2017…
• Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States April 5, 2021 J Med Econ. 2021 Apr 5:1. doi: 10.1080/13696998.2021.1913009. Online ahead of print.ABSTRACTAIMS: Within 5 years of initiating carbidopa/levodopa, ∼50% of patients with Parkinson's disease (PD) experience "OFF" episodes; little is known about the cost burden. We investigated the association of "OFF" episodes with patient characteristics, healthcare resource utilization (HCRU), and healthcare costs.METHODS: Analyses used neurologist-provided data from the US-specific 2017…
• Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States April 5, 2021 J Med Econ. 2021 Apr 5:1. doi: 10.1080/13696998.2021.1913009. Online ahead of print.ABSTRACTAIMS: Within 5 years of initiating carbidopa/levodopa, ∼50% of patients with Parkinson's disease (PD) experience "OFF" episodes; little is known about the cost burden. We investigated the association of "OFF" episodes with patient characteristics, healthcare resource utilization (HCRU), and healthcare costs.METHODS: Analyses used neurologist-provided data from the US-specific 2017…
• FDA Approves Kynmobi Sublingual Film to Treat Off Episodes in Parkinson’s May 22, 2020 The U.S. Food and Drug Administration has approved Sunovion’s Kynmobi (apomorphine hydrochloride) as an on-demand sublingual treatment for off episodes, or times when medication wears off, in people with Parkinson’s disease. The medication, formerly known as APL-130277, is an apomorphine film that is placed under-the-tongue (sublingual administration) when patients start experiencing a worsening of their symptoms. It can be taken up to five…
• When Parkinson’s OFF Gets in the Way of Life December 8, 2020 Parkinson’s looks different for everyone, and so do Parkinson’s OFF times. Some people living with Parkinson’s know they are OFF when their motor symptoms, such as tremor, rigidity, slowness, and stiffness return. Others may be aware that as their medications wear off, they feel increased anxiety, fatigue, depression, or pain. Some people with Parkinson’s may not even be aware that what they are feeling…
• FDA Accepts Resubmitted New Drug Application for APL-130277 Apomorphine Film, Sunovion Announces January 6, 2020 The U.S. Food and Drug Administration has accepted Sunovion‘s resubmitted new drug application (NDA) for APL-130277, an oral apomorphine therapy for treating off episodes in Parkinson’s disease. The FDA had asked for additional information regarding APL-130277, following the first NDA in mid-2018. A response to this resubmission is expected by May 21. APL-130277 is an under-the-tongue (sublingual) apomorphine film that…
• The Science of Parkinson’s OFF November 16, 2020 Although the terms ON and OFF have been used to describe responses to levodopa therapy for more than 40 years, there is still no universally agreed-upon definition for the term OFF, and everyone with Parkinson’s experiences it differently. OFF periods occur when your medication isn’t working optimally, and your motor and non-motor symptoms return. OFF is much more nuanced but understanding its scientific causes…
• The Science of Parkinson’s OFF November 16, 2020 Although the terms ON and OFF have been used to describe responses to levodopa therapy for more than 40 years, there is still no universally agreed-upon definition for the term OFF, and everyone with Parkinson’s experiences it differently. OFF periods occur when your medication isn’t working optimally, and your motor and non-motor symptoms return. OFF is much more nuanced but understanding its scientific causes…
• Words with Hope December 8, 2021 “There is no medicine like hope, no incentive so great, and no tonic so powerful as expectation of something better tomorrow.” Orison Swett Marden “Hope is a waking dream.” Aristotle Introduction: Over the years, I have used blog posts about a specific word, feeling, or emotion. A frequent word used a lot here is the word ‘hope’. To some, hope may…
• Sublingual Film Turns Parkinson’s Off Periods ‘Full On,’ Most Patients in Phase 3 Trial Report February 18, 2020 A majority of Parkinson’s patients in a clinical trial reported achieving a fully “on” response within 30 minutes of taking Sunovion‘s under-the-tongue apomorphine film, called APL-130277, about three months after starting its use to counter “off” episodes in this disease, a post-hoc analysis of study results found. At week 12, 79% of the 54 adults using APL-130277 in the Phase…
• Sublingual Film Turns Parkinson’s Off Periods ‘Full On,’ Most Patients in Phase 3 Trial Report February 18, 2020 A majority of Parkinson’s patients in a clinical trial reported achieving a fully “on” response within 30 minutes of taking Sunovion‘s under-the-tongue apomorphine film, called APL-130277, about three months after starting its use to counter “off” episodes in this disease, a post-hoc analysis of study results found. At week 12, 79% of the 54 adults using APL-130277 in the Phase…
• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes June 17, 2020 MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or…
• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes June 17, 2020 MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or…
• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes June 17, 2020 MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or…
• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes June 17, 2020 MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or…
• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes June 17, 2020 MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or…
• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes June 17, 2020 MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or…
• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes June 17, 2020 MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or…
• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes June 17, 2020 MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or…
• Long-term Gocovri Lessens Parkinson’s Motor Symptoms for at Least 2 Years, Final Phase 3 Data Show February 20, 2020 Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show. “As the longest-running amantadine study to date, this open-label trial suggests Gocovri may provide sustained improvement in both dyskinesia and OFF…
• Long-term Gocovri Lessens Parkinson’s Motor Symptoms for at Least 2 Years, Final Phase 3 Data Show February 20, 2020 Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show. “As the longest-running amantadine study to date, this open-label trial suggests Gocovri may provide sustained improvement in both dyskinesia and OFF…